| (AstraZeneca) D419CC00002 / HIMALAYA | A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma | Zbuk, Dr Kevin | Open | NCT03298451 |
| (MacroGenics) CP-MGAH22-05 | A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer | Juergens, Dr Rosalyn | Open | NCT02689284 |
| (Merck) MK-3475-590 / KEYNOTE 590 | A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590) | Juergens, Dr Rosalyn | Open | NCT03189719 |
| (PMH) OZM-067 / LuNET | A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment with individualized dosimetry in Patients with 68Ga-DOTATATE identified Somatostatin Receptor Positive Neuroendocrine Tumors | Juergens, Dr Rosalyn | Open | NCT02743741 |
| RTOG 1112 | Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | Swaminath, Dr Anand | Open | NCT01730937 |
| (CCTG) CO.21 / CHALLENGE | A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) | Goffin, Dr John | On hold | NCT00819208 |
Find a Trial
Contact Us